Beginning in 1960 in Geneva and occurring every 5 years since 1998, the World Symposium on Pulmonary Hypertension (WSPH) brings together stakeholders from around the world to highlight the scientific advances and future needs of the pulmonary hypertension (PH) field. The seventh edition of the WSPH recently convened in Barcelona, Spain, from June 29 to July 1, 2024. The symposium included 15 task force sessions developed over 2 years with documents summarizing the results, which were recently published in the European Respiratory Journal.

To assess the association between the use of adaptive pacing on clinical and economic outcomes of cardiac resynchronization therapy (CRT) recipients in a real-world analysis.

The left ventricular assist device (LVAD) has revolutionized clinical management of advanced heart failure.1 Despite the overarching goal of offloading the heart and improving vital-organ perfusion, little is known regarding the impact of LVAD physiology on cerebral blood flow (CBF). A few small cohorts have encouragingly demonstrated improvement in cerebrovascular health after HeartMate 3 (HM3) (Abbott Industrials, Abbott Park, IL) implantation.2 In clinical practice, the LVAD speed can be titrated to optimize cardiopulmonary hemodynamics, but the impact of speed titration on CBF represents a critical knowledge gap.

Heart failure with preserved ejection fraction (HFpEF) makes up ∼ 50% of HF cases of HF, and it shows increasing prevalence.1 HFpEF is characterized by high filling pressures as well as exercise intolerance and exertional symptomology as cardinal features. Peripheral abnormalities contribute significantly to the reduced exercise tolerance in those with HFpEF,2 including the abnormal distribution of blood flow to skeletal muscle, which may elicit a mismatch between oxygen supply and demand.2 Limb blood flow responses are lower in HFpEF compared to healthy controls during knee-extension exercise.